Want to join the conversation?
Biotechnology company $UTHR said it has announced receipt of a Paragraph IV Certification Notice Letter on Feb. 18, 2016 from Actavis advising that Actavis has submitted an ANDA to the U.S. Food and Drug Administration (FDA) requesting approval to market a generic version of the 2.5 mg strength of Orenitram (treprostinil) Extended-Release Tablets.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.